- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 10.49 License, Supply and Distribution Agreement Effective April 9, 2019 by and Between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA
- 10.50 License, Supply and Distribution Agreement Effective March 6, 2019 by and Between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA
- 10.51 Development Agreement Effective December 3, 2018 by and Between Mikah Pharma LLC and Elite Laboratories, Inc. (Portions of This Agreement Have Been Redacted In Compliance with Regulation S-K Item 601(B)(10))*
- 21 Subsidiary of the Company
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Elite Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended March 31, 2019 filed with Securities and Exchange Commission (the “Report”), I, Carter J. Ward, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. | The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and | |
2. | The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented. |
Date: June 21, 2019 | /s/ Carter Ward |
Carter J. Ward, Chief Financial Officer |
This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.